It was reported that PSA level could be influenced by smoking status, Gleason score, and 5α-reductase inhibitor for benign prostate hyperplasia treatment, but not associated with other clinical factors including hypercholesterolemia in a retrospective study (87, 88). The gene discussed is KLK3; the disease is benign prostatic hyperplasia.